Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia

Blood Reviews

Volumn 14, Issue 4, 2000, Pages 182-189

  Oosterveld, M ^a   De Witte, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; HLA ANTIGEN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; HIGH RISK POPULATION; HUMAN; MORTALITY; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0034490503     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2000.0139     Document Type: Article

References (65)

1. Myelodysplastic syndromes: A scoring system with prognostic significance
2. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes
3. Malignancies due to occupational exposure to benzene
4. Increasing prevalence of the myelodysplastic syndrome. An international Delphi study
5. Epidemiological and etiological aspects of myelodysplastic syndromes
6. Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure
7. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease
8. Therapy related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy
9. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series
10. Proposals for the classification of the myelodysplastic syndromes
11. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients
12. Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposal for an improved scoring system
13. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases
14. Prognostic features of chronic myelomonocytic leukemia: A modified Bournemouth score gives the best prediction of survival
15. Clinical implications of chromosomal abnormalities in 401 patients with MDS: A multicentre study in Japan
16. Myelodysplastic syndromes
17. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes
18. International Scoring System for evaluating prognosis in myelodysplastic syndromes
19. Application of the International Prognosteic Scoring System for myelodysplastic syndromes
20. Application of the International Scoring System for myelodysplasia to M.D. Anderson patients
21. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
22. Cytogenetics
23. Treatment of therapy-related leukemia and myelodysplastic syndromes
24. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes
25. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
26. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukemia
27. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 form a single institution confirms the importance of cytogenetics
28. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes
29. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome
30. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: A survey of the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
31. Factors influencing outcome in de-novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients
32. Treatment Of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogenic BMT
33. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia
34. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes
35. Bone marrow transplantation for patients with myelodysplasia
36. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimen and analysis of prognostic factors
37. An update on allogeneic marrow transplantation for myelodysplastic syndrome
38. Prognostic variables in bone marrow transplantation for secondary leukemia and myelodysplastic syndromes: A survey of the working party on leukemia
39. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
40. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
41. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy
42. Cytogenetic abnormalities in primary myeldysplastic syndrome are highly predictive of outcome after bone marrow transplantation
43. Bone marrow transplantation for therapy-related myelodysplasia: Comparison with primary myelodysplasia
44. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation
45. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia
46. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia
47. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical siblings and alternative donors
48. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey
49. Effect of chemotherapy for the dysmyelopoietic syndrome
50. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute leukemia
51. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy
52. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia following MDS of more than 6 months duration
53. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of myelodysplastic syndromes and acute myeloid leukaemia
54. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
55. Autologous bone marrow transplantation with marrow purged by Mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): A pilot study
56. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
57. Groupe Français des Myélodysplasies (GFM) and Groupe Ouest-Est d'étude des Leucémies aiguës myéloïdes (GOELAMS)
58. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia
59. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes
60. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes
61. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukemia
62. Peripheral blood stem cell mobilization after chemotherapy in patients with high risk myelodysplastic syndrome
63. Donor leukocyte transfusions for relapse in myelodysplastic syndrome after allogeneic marrow transplantation
64. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplant